Target intelligence / Profile preview

Transmembrane p24 trafficking protein 2 (TMED2)

Target
TMED2
Molecular classification
Cargo receptor, Transmembrane protein, Member of the p24/TMED family, Secretory pathway regulator, Protein trafficking factor
01

Overview

Transmembrane p24 trafficking protein 2 (TMED2) is a member of the TMED/p24 protein family, which regulates the trafficking of proteins between the endoplasmic reticulum (ER) and the Golgi apparatus. TMED2 serves as a cargo receptor, important for the selection and packaging of cargo into vesicles coated with COPI and COPII proteins. It is involved in both anterograde (ER to Golgi) and retrograde (Golgi to ER) transport, mainly by interacting with other TMED family members such as TMED10, and is implicated in the organization of secretory pathway organelles and in maintaining Golgi structure. TMED2 impacts the regulation of G protein-coupled receptor (GPCR) trafficking, innate immune signaling such as the STING/MITA pathway, and overall quality control of protein folding. Dysregulation or mutation of TMED2 is implicated in a wide range of diseases, especially different cancers, congenital disorders, cardiomyopathy, and immune dysfunction[1][3][4]. TMED2 is potentially a therapeutic target, but direct pharmacological modulators are not yet available, and manipulation may have systemic effects due to its fundamental role in protein secretion and cellular homeostasis.

Other names
TMED2p24 beta subunitp24 protein family member betaTransmembrane emp24 domain-containing protein 2
02

Mechanism of action

No direct mechanisms of drug action targeting TMED2 are annotated; therapeutic modulation would presumably target trafficking or inflammatory pathways.

03

Biological functions

Vesicular protein trafficking (ER-to-Golgi and return)Cargo receptor for secretory moleculesOrganization and maintenance of Golgi apparatusQuality control of folded cargo proteinsRegulation of GPCR exocytic traffickingModulation of innate immune responses (e.g., STING/MITA signaling pathway)
04

Disease associations

Cancer (including lung, breast, head and neck, ovarian, gastrointestinal etc.)InflammationCardiomyopathy (dilated cardiomyopathy)Congenital malformationsImmune disordersNeurodegenerative diseaseDiabetes
05

Safety considerations

Embryonic lethality with allelic disruption in model systemsPotential impact on global protein secretion and immune responses if targeted therapeutically

Beyond the preview

Go deeper on Transmembrane p24 trafficking protein 2 (TMED2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane p24 trafficking protein 2 (TMED2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call